Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy

Digestive and Liver Disease

Volumn 46, Issue 5, 2014, Pages 427-432

  Ieluzzi, Donatella ^a,b   Covolo, Loredana ^c   Donato, Francesco ^c   Fattovich, Giovanna ^a,d  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Chronic hepatitis B; Cirrhosis; Hepatocellular carcinoma; Liver related mortality; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; INTERFERON; PEGINTERFERON ALPHA; VIRUS DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IL28A PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER MORTALITY; CANCER RISK; CAUCASIAN; CAUSE OF DEATH; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT RESPONSE; VIRUS REPLICATION; AGE; BLOOD; DELTA AGENT HEPATITIS; EPIDEMIOLOGY; GENETICS; HETEROZYGOTE; IMMUNOLOGY; LIVER TUMOR; LONGITUDINAL STUDY; PHYSIOLOGY; VIROLOGY;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS D; HUMANS; INCIDENCE; INTERLEUKINS; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RISK FACTORS; VIRUS REPLICATION;

EID: 84898904886     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.01.003     Document Type: Article

References (20)

1. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008, 48:335-352.
2. Hadziyannis S.J. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. Journal of Hepatology 2011, 55:183-191.
3. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
4. Fattovich G., Brollo L., Giustina G., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32:294-298.
5. Fattovich G., Rugge M., Brollo L., et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986, 6:167-172.
6. Gaiani S., Gramantieri L., Venturoli N., et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. Journal of Hepatology 1997, 27:979-985.
7. Acute and chronic hepatitis revisited. Review by an international group. Lancet 1977, 2:914-919.
8. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology 1991, 13:372-374.
9. Moreno-Otero R., Garcia-Monzon C., Garcia-Sanchez A., et al. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. American Journal of Gastroenterology 1991, 86:560-564.
10. Mazzella G., Saracco G., Festi D., et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. American Journal of Gastroenterology 1999, 94:2246-2250.
11. Fattovich G., Brollo L., Alberti A., et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988, 8:1651-1654.
12. Brunetto M.R., Oliveri F., Rocca G., et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989, 10:198-202.
13. Brunetto M.R., Oliveri F., Coco B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. Journal of Hepatology 2002, 36:263-270.
14. Iloeje U.H., Yang H.I., Jen C.L., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
15. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
16. Zoutendijk R., Reijinders J.G.P., Zoulim F., et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013, 62:760-765.
17. Lampertico P., Soffredini R., Viganò M., et al. 5-Year entecavir treatment in NUC-naive, field practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics [abstract]. Journal of Hepatology 2013, 58(Suppl. 1):S306.
18. Papatheodoridis G., Manolakopoulos S., Touloumi G., et al. Hepatocellular carcinoma [HCC] risk in HBeAg-negative chronic hepatitis B [CHBe-] with or without cirrhosis treated with entecavir: results of the nationwide HepNet.Greece cohort study [abstract]. Journal of Hepatology 2013, 58(Suppl. 1):S312.
19. Sonneveld M.J., Wong V.W., Woltman A.M., et al. Polymorphisms near IL28B and serologic response to Peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142:513-520.
20. Lampertico P., Viganò M., Cheroni C., et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896.